Dallah Healthcare Company

SASE:4004 Stock Report

Market Cap: ر.س12.5b

Dallah Healthcare Valuation

Is 4004 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4004 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ر.س138.62
Fair Value
10.6% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: 4004 (SAR123.9) is trading below our estimate of fair value (SAR138.62)

Significantly Below Fair Value: 4004 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4004?

Key metric: As 4004 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4004. This is calculated by dividing 4004's market cap by their current earnings.
What is 4004's PE Ratio?
PE Ratio23.4x
Earningsر.س535.63m
Market Capر.س12.51b

Price to Earnings Ratio vs Peers

How does 4004's PE Ratio compare to its peers?

The above table shows the PE ratio for 4004 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.3x
4002 Mouwasat Medical Services
18.7x10.95%ر.س14.1b
4017 Dr. Soliman Abdel Kader Fakeeh Hospital
27.3x16.40%ر.س8.2b
4018 Almoosa Health
36.2x21.10%ر.س7.5b
4005 National Medical Care
19.2x9.25%ر.س6.4b
4004 Dallah Healthcare
23.4x14.61%ر.س12.5b

Price-To-Earnings vs Peers: 4004 is good value based on its Price-To-Earnings Ratio (23.4x) compared to the peer average (25.3x).

Price to Earnings Ratio vs Industry

How does 4004's PE Ratio compare vs other companies in the SA Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
4004 23.4xIndustry Avg. 23.4xNo. of Companies4PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4004 is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the SA Healthcare industry average (23.4x).

Price to Earnings Ratio vs Fair Ratio

What is 4004's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4004 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.4x
Fair PE Ratio22.7x

Price-To-Earnings vs Fair Ratio: 4004 is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the estimated Fair Price-To-Earnings Ratio (22.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4004 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س123.90
ر.س140.30
+13.24%
15.52%ر.س175.00ر.س106.00n/a8
Dec ’26ر.س125.70
ر.س142.05
+13.01%
15.15%ر.س175.00ر.س106.00n/a8
Nov ’26ر.س154.00
ر.س147.18
-4.43%
17.28%ر.س183.00ر.س106.00n/a8
Oct ’26ر.س147.40
ر.س142.49
-3.33%
16.58%ر.س183.00ر.س106.00n/a9
Sep ’26ر.س127.90
ر.س143.14
+11.92%
15.46%ر.س183.00ر.س106.00n/a10
Aug ’26ر.س136.00
ر.س137.76
+1.29%
20.77%ر.س183.00ر.س92.20n/a10
Jul ’26ر.س130.00
ر.س142.33
+9.48%
21.29%ر.س183.00ر.س92.20n/a11
Jun ’26ر.س119.80
ر.س147.66
+23.26%
19.65%ر.س183.00ر.س92.20n/a10
May ’26ر.س120.60
ر.س147.37
+22.20%
20.07%ر.س183.00ر.س89.30n/a10
Apr ’26ر.س126.60
ر.س159.08
+25.66%
13.78%ر.س183.00ر.س113.00n/a10
Mar ’26ر.س144.20
ر.س164.58
+14.13%
13.46%ر.س192.00ر.س117.00n/a10
Feb ’26ر.س159.20
ر.س164.78
+3.51%
13.50%ر.س192.00ر.س117.00n/a10
Jan ’26ر.س151.00
ر.س164.78
+9.13%
13.50%ر.س192.00ر.س117.00n/a10
Dec ’25ر.س150.80
ر.س163.58
+8.47%
12.88%ر.س192.00ر.س117.00ر.س125.7010
Nov ’25ر.س159.60
ر.س163.38
+2.37%
13.17%ر.س192.00ر.س115.00ر.س154.0010
Oct ’25ر.س160.00
ر.س163.78
+2.36%
13.31%ر.س192.00ر.س115.00ر.س147.4010
Sep ’25ر.س160.00
ر.س162.87
+1.79%
14.00%ر.س192.00ر.س115.00ر.س127.909
Aug ’25ر.س161.80
ر.س156.20
-3.46%
13.99%ر.س183.00ر.س109.00ر.س136.009
Jul ’25ر.س154.20
ر.س155.88
+1.09%
12.96%ر.س183.00ر.س109.00ر.س130.0010
Jun ’25ر.س165.00
ر.س155.18
-5.95%
12.91%ر.س183.00ر.س109.00ر.س119.8010
May ’25ر.س162.00
ر.س154.38
-4.70%
13.23%ر.س183.00ر.س106.00ر.س120.6010
Apr ’25ر.س171.40
ر.س150.09
-12.43%
12.52%ر.س174.00ر.س106.00ر.س126.609
Mar ’25ر.س187.60
ر.س147.26
-21.51%
16.02%ر.س165.00ر.س85.80ر.س144.209
Feb ’25ر.س165.20
ر.س142.37
-13.82%
16.75%ر.س165.00ر.س85.80ر.س159.209
Jan ’25ر.س170.40
ر.س142.37
-16.45%
16.75%ر.س165.00ر.س85.80ر.س151.009
Dec ’24ر.س166.00
ر.س136.70
-17.65%
16.90%ر.س165.00ر.س85.80ر.س150.809
ر.س140.3
Fair Value
11.7% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/09 13:54
End of Day Share Price 2025/12/09 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dallah Healthcare Company is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ibrahim ElaiwatAljazira Capital Company
Jassim Al-JubranAljazira Capital Company
Rim Ben Salah GharbiAlphaMena